Research advances on immune-combination strategy in bladder-sparing treatment for bladder cancer
10.3969/j.issn.1009-8291.2025.10.015
- VernacularTitle:膀胱癌保膀胱治疗的免疫联合策略研究进展
- Author:
Jinyuan CHEN
1
;
Dongliang ZHANG
1
;
Jialiang SHAO
1
;
Xiang WANG
1
Author Information
1. 上海交通大学医学院附属第一人民医院泌尿外科,上海 200080
- Publication Type:Journal Article
- Keywords:
bladder cancer;
muscle-invasive bladder cancer;
high-risk non-muscle invasive bladder cancer;
immunotherapy;
bladder-preserving;
trimodal therapy;
bacillus calmette-guérin
- From:
Journal of Modern Urology
2025;30(10):903-908
- CountryChina
- Language:Chinese
-
Abstract:
Bladder-preserving treatment has become a research focus due to its potential to balance therapeutic efficacy and quality of life.In recent years,the rapid development of immunotherapy has brought new opportunities for bladder-sparing strategies.In high-risk non-muscle invasive bladder cancer(HR-NMIBC),emerging regimens such as bacillus calmette-guérin-based immunoenhancement,immuno-chemotherapy combinations,targeted therapy,and gene therapy have demonstrated encouraging efficacy and safety in trials like GU-123 and TRUCE-02,with complete remission rate ranging from 42％-100％.In muscle-invasive bladder cancer(MIBC),immunotherapy is being integrated with trimodal therapy,radiotherapy,chemotherapy,and antibody-drug conjugates,as evidenced by studies such as ReBirth and BTCRC-GU15-023,which reported significant improvements in bladder-intact event-free survival,progression-free survival,and complete remission rate.This review summarizes the latest advances in immunotherapy-based bladder-preserving strategies for both HR-NMIBC and MIBC,aiming to provide insights for future individualized treatment approaches.
